-
Nonselective β-Blockade Impairs HCT Recovery
2026-08-27
The reference study shows that nonselective β-adrenergic receptor inhibitors can delay hematopoietic regeneration after allogeneic hematopoietic cell transplantation, whereas β1-selective inhibition has a less evident effect. By integrating mouse transplantation models with human cohort analyses, the work identifies β-blocker selectivity as a clinically relevant variable in post-transplant engraftment.
-
ABT-263: Mapping Paracrine Apoptotic Resistance
2026-08-26
ABT-263 (Navitoclax) is more than a Bcl-2-family inhibitor: it can serve as a controlled probe of mitochondrial apoptotic priming and stress-induced resistance. This article translates FGF-dependent, non-cell-autonomous findings into practical apoptosis assay strategies for cancer biology and pediatric acute lymphoblastic leukemia models.
-
Cholecystokinin octapeptide ammonium in Assays
2026-08-26
A scenario-driven guide to using Cholecystokinin octapeptide ammonium in cell and zebrafish studies, with practical controls for receptor biology, solubility, dosing, and interpretation. SKU C8717 is evaluated through evidence-based workflow decisions rather than unsupported performance claims.
-
VE-821: ATR Checkpoint Logic Beyond DNA Repair
2026-08-25
VE-821 is a selective ATR kinase inhibitor for dissecting checkpoint signaling, radiosensitization, and DNA repair pathway research. This article develops a causal assay framework linking ATR perturbation with, but not conflating it with, DNMT1-dependent HBoV1 replication and RNA processing.
-
Gepotidacin Workflows for Antibacterial Research
2026-08-25
Build more informative antibacterial assays with Gepotidacin, from concentration-controlled susceptibility testing to orthogonal topoisomerase and DNA-break readouts. This workflow distinguishes direct target engagement from downstream growth effects and helps researchers investigate fluoroquinolone-resistant phenotypes with better experimental control.
-
Carvedilol: Receptor Context in HCT Research
2026-08-24
Carvedilol is a β-adrenergic receptor antagonist whose effects extend from cardiovascular signaling to redox biology and hematopoietic regeneration. This article presents a context-first framework for separating receptor, antioxidant, vascular, and transplant-related phenotypes in research assays.
-
Lisinopril Dihydrate: ACE Inhibition Workflows
2026-08-24
Build reproducible ACE inhibition assays with a water-compatible, long-acting reference compound suited to cardiovascular and renal disease models. The workflow combines concentration planning, orthogonal pathway readouts, aminopeptidase counter-screens, and practical troubleshooting for more defensible results.
-
Dronedarone (Multaq): A Mechanistic Assay Lens
2026-08-23
Dronedarone (Multaq) can serve as more than a standard antiarrhythmic control. This article explains how its ion-channel profile, KCa2 assay evidence, and formulation characteristics support rigorous atrial fibrillation treatment research and cardiac target deconvolution.
-
XPO1 Inhibition Sensitizes GCB-DLBCL to Platinum
2026-08-22
A 2026 study found that selinexor-mediated XPO1 inhibition increases the response of diffuse large B-cell lymphoma cells to cisplatin and oxaliplatin, with especially strong effects in germinal-center B-cell-like DLBCL. The work connects combination cytotoxicity to apoptosis, reactive oxygen species accumulation, DNA-damage signaling, and altered AKT/mTOR and JNK/ATM/p53 pathways, providing a rationale for further preclinical evaluation.
-
Angiotensin 1/2 (5-7) in Cell Assays
2026-08-21
Learn how Angiotensin 1/2 (5-7), SKU A1049, can improve experimental control in cell viability, proliferation, cytotoxicity, and renin–angiotensin system studies. This scenario-based guide covers peptide identity, solubility, storage, assay interpretation, cross-domain SARS-CoV-2 research, and practical vendor-selection criteria.
-
iPSC Platform for Ultrarare Disease Trials
2026-08-20
Sequiera et al. developed a patient-specific iPSC platform to prescreen therapies for an ultrarare ECHS1-associated Leigh-like syndrome before further clinical trial exposure. The study shows how matched healthy and disease controls, multisystem modeling, and metabolic profiling can support more informed treatment selection when genotype-specific evidence is scarce.
-
Tioconazole Workflows for Antifungal Research
2026-08-20
Build more reproducible Tioconazole screens with solvent-aware preparation, orthogonal fungal readouts, and stress-state controls. This workflow connects ergosterol-focused antifungal assays with disciplined experimental design inspired by recent DNA-repair research, without overextending the evidence.
-
Thiazovivin (A5506): Practical ROCK Inhibition
2026-08-19
Thiazovivin is a ROCK inhibitor for research workflows involving fibroblast reprogramming, induced pluripotent stem cell generation, and human embryonic stem cell survival after dissociation. This guide covers handling, stock preparation, controls, and troubleshooting; the compound is not intended for diagnostic, therapeutic, or clinical use.
-
SIX1 Control of Lipogenesis in Liver Cancer
2026-08-19
The reference study identifies SIX1 as a direct transcriptional regulator of de novo lipogenesis in liver cancer cells, linking ACLY, FASN, and SCD1 expression to a DGUOK-AS1–miR-145-5p regulatory axis. Its findings connect lipid metabolic control with tumor proliferation, invasion, and metastasis, while highlighting DGUOK-AS1 as a potential prognostic indicator and therapeutic entry point.
-
Pemetrexed: Linking Folate Stress to DNA Repair
2026-08-18
Pemetrexed is more than a broad cytotoxic control: it can serve as a mechanistic probe connecting folate-dependent nucleotide depletion with DNA-repair phenotypes. This guide shows how to build better tumor-cell assays around pemetrexed disodium and interpret results in malignant mesothelioma research.